Drug Trial Radar · NCT03762109
The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery
Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Jul 29, 2019
Primary completion
Jun 1, 2024
Study completion Jun 1, 2024
Sponsor
- Lead sponsor
- Beth Israel Deaconess Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether administration of a non-centrally acting muscle relaxants will improve the Overall Benefit of Analgesia Score (OBAS), and Richmond Agitation Sedation Scale (RASS) scores in patients undergoing lumbar fusion.
Conditions
- Lumbar Spine Injury
Interventions
DantroleneDrug
muscle relaxant
Placebo Oral TabletDrug
inactive pill
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Benefit of Analgesia Score (OBAS)Time frame: Measured at 24 hours after surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.